<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029950</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-02426</org_study_id>
    <secondary_id>NCI-2013-02426</secondary_id>
    <secondary_id>NA_00089739</secondary_id>
    <secondary_id>J13128</secondary_id>
    <secondary_id>9524</secondary_id>
    <secondary_id>9524</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>UM1CA186691</secondary_id>
    <secondary_id>UM1CA186704</secondary_id>
    <nct_id>NCT02029950</nct_id>
  </id_info>
  <brief_title>Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin, and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of pomalidomide after combination
      chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or high-risk
      myelodysplastic syndrome. Drugs used in chemotherapy, such as cytarabine, daunorubicin
      hydrochloride, and etoposide, work in different ways to stop the growth of cancer cells,
      either by killing the cells, by stopping them from dividing, or by stopping them from
      spreading. Pomalidomide may kill cancer cells by stopping blood flow to the cancer and by
      stimulating white blood cells to kill cancer cells. Giving more than one drug (combination
      chemotherapy) and pomalidomide may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To define the maximum tolerated dose (MTD) of pomalidomide when given at the time of early
      lymphocyte recovery following intensive induction timed sequential therapy (TST) with
      cytarabine (cytosine arabinoside), daunorubicin hydrochloride (daunorubicin) and etoposide
      (AcDVP-16) in patients with newly diagnosed intermediate- and poor-risk acute myeloid
      leukemia and high-risk myelodysplastic syndrome (MDS).

      II. To evaluate the safety, tolerability and toxicity of pomalidomide given at the time of
      early lymphocyte recovery following induction AcDVP-16 chemotherapy in adults with newly
      diagnosed intermediate- and poor-risk acute myeloid leukemia and high-risk MDS.

      SECONDARY OBJECTIVES:

      I. To evaluate the safety, tolerability and toxicity of pomalidomide given as a continuation
      therapy following induction and/or consolidation chemotherapy in adults with newly diagnosed
      intermediate- and poor-risk acute myeloid leukemia and high-risk MDS.

      II. To document responses (complete remission [CR], CR with incomplete count recovery [CRi],
      partial remission [PR]) to AcDVP-16 followed by pomalidomide at the time of lymphocyte
      recovery in newly diagnosed adults with intermediate- and poor-risk acute myeloid leukemia
      (AML) and high-risk MDS, including duration of response, disease-free and overall survival.

      III. Correlative pharmacodynamics studies: a) to characterize the effects of pomalidomide on
      the functional dynamics of different lymphocyte subpopulations (effector T [Teff], regulatory
      T [Treg], natural killer [NK] cells) and its impact on tumor-associated antigen
      (TAA)-specific T cell immunity when given following induction and as a maintenance; b) to
      examine for the presence of minimal residual disease (MRD) before and after pomalidomide
      administration during induction and continuation therapy; c) to examine cereblon expression
      in primary leukemia cells at diagnosis and in sorted T cells prior to and after pomalidomide
      treatment.

      OUTLINE: This is a dose-escalation study of pomalidomide.

      INDUCTION: Patients receive cytarabine intravenously (IV) continuously and daunorubicin
      hydrochloride IV on days 1-3 (patients may otherwise receive idarubicin hydrochloride IV over
      10-15 minutes on days 1-3 if daunorubicin hydrochloride is unavailable), and etoposide IV
      over 3 hours on days 8-10. At the time of early lymphocyte recovery (after day +14), patients
      also receive pomalidomide orally (PO) for 10-21 days.

      CONSOLIDATION: Patients achieving CR or CRi receive cytarabine based treatment at the
      discretion of the treating investigator, with possible regimens comprising cytarabine IV
      continuously on days 1-3, and 10-12 and daunorubicin hydrochloride IV on days 1-3, or high-
      or medium-dose cytarabine IV every 12 hours on days 1, 3, and 5 for 1-4 courses.

      CONTINUATION: Patients achieving CR or CRi who did not undergo allogeneic stem cell
      transplant receive pomalidomide PO daily on days 1-21 beginning 6 weeks following blood count
      recovery. Treatment repeats every 4-6 weeks for up to 4 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 16, 2013</start_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of pomalidomide, defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in 6 patients according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>The proportion of dose-limiting toxicities at each dose level will be reported with exact binomial 95% confidence intervals. Adverse events will be summarized by dose level for all doses. All toxicities by type and grade will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of toxicities in the expansion cohort graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The proportion of toxicities by type and grade in the expansion cohort will be reported with exact binomial 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving complete remission, complete remission with incomplete count recovery, or partial remission</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The proportion of patients achieving each category of response will be reported with 95% exact binomial confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from start of treatment to time of progression or relapse or death, assessed up to 2 years</time_frame>
    <description>Standard life table methods will be used to analyze progression-free survival. One-year and median progression-free survival with 95% confidence intervals will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time of enrollment onto this study to the time of death, assessed up to 2 years</time_frame>
    <description>Standard life table methods will be used to analyze overall survival.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in lymphocyte subpopulations</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <description>Boxplots and line plots will be used to visual trends in the lymphocyte subpopulations. Changes and percentage changes in variables will be summarized. 95% confidence intervals will be obtained by exponentiating the endpoints of confidence intervals for the differences of mean logarithms. A regression model using generalized estimating equations or mixed model used to assess T cell changes. Association of bone marrow and peripheral blood measurements assessed using scatterplots and Spearman's rank correlation coefficients.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in levels of antigen-specific CD8+ T cell responses</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <description>McNemar's test will be used to compare proportions with positive tumor specificity before and after pomalidomide treatment. Sensitivity and specificity of induction responses for predicting complete remission status will be estimated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence of minimal residual disease-leukemic stem cells in marrow</measure>
    <time_frame>Day 14</time_frame>
    <description>Presence or absence of minimal residual disease on day 14 will be correlated with minimal residual disease following induction pomalidomide. McNemar's test will be used to compare proportions. Presence or absence of residual leukemic stem cells immediately following induction will be correlated with progression-free survival using the Kaplan-Meier survival method.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in level of cereblon expression in acute myeloid leukemia cells and sorted T cells</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <description>Will examine in relation to clinical parameters as well as T cell reconstitution.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Blasts 10-19 Percent of Bone Marrow Nucleated Cells</condition>
  <condition>Blasts 20 Percent or More of Bone Marrow Nucleated Cells</condition>
  <condition>Blasts 5-19 Percent of Peripheral Blood White Cells</condition>
  <condition>Chronic Myelomonocytic Leukemia-2</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Previously Treated Myelodysplastic Syndrome</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (combination chemotherapy, pomalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, pomalidomide)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, pomalidomide)</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>Cloridrato de Daunorubicina</other_name>
    <other_name>Daunoblastin</other_name>
    <other_name>Daunoblastina</other_name>
    <other_name>Daunoblastine</other_name>
    <other_name>Daunomycin Hydrochloride</other_name>
    <other_name>Daunomycin, hydrochloride</other_name>
    <other_name>Daunorubicin.HCl</other_name>
    <other_name>Daunorubicini Hydrochloridum</other_name>
    <other_name>FI-6339</other_name>
    <other_name>Ondena</other_name>
    <other_name>RP-13057</other_name>
    <other_name>Rubidomycin Hydrochloride</other_name>
    <other_name>Rubilem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, pomalidomide)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, pomalidomide)</arm_group_label>
    <other_name>Idamycin</other_name>
    <other_name>Idarubicin HCl</other_name>
    <other_name>IMI-30</other_name>
    <other_name>SC-33428</other_name>
    <other_name>Zavedos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (combination chemotherapy, pomalidomide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (combination chemotherapy, pomalidomide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (combination chemotherapy, pomalidomide)</arm_group_label>
    <other_name>4-Aminothalidomide</other_name>
    <other_name>Actimid</other_name>
    <other_name>CC-4047</other_name>
    <other_name>Imnovid</other_name>
    <other_name>Pomalyst</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed:

               -  Pathologically confirmed intermediate or poor risk newly diagnosed AML (subtypes
                  M0, 1, 2, 4-7), but excluding newly diagnosed core-binding factor (CBF) (t(8;21)
                  or M4eo subtype (inv(16) or t(16;16) AMLs and acute promyelocytic leukemia (acute
                  promyelocytic leukemia [APL], M3)

               -  MDS with high risk features as defined by intermediate (INT)-2 or high
                  International Prognostic Scoring System (IPSS) score with &gt; 10% blasts in the
                  bone marrow

               -  Chronic myelomonocytic leukemia-2 (CMML-2) defined as having &gt; 10% blasts
                  (including promonocytes) in the bone marrow or 5-19% blasts (including
                  promonocytes) in the peripheral blood

          -  Patients who have received hydroxyurea alone or have received non-cytotoxic therapies
             previously for treatment of MDS or myeloproliferative neoplasm (MPN) (e.g.
             azacitidine, decitabine, histone deacetylase inhibitors, tyrosine kinase inhibitors,
             hematopoietic growth factors, interferon, lenalidomide, thalidomide) will be eligible
             for this trial as long as immunomodulatory drugs (e.g. lenalidomide, thalidomide) have
             not been used in the past 3 months

          -  Patients must be off all non-cytotoxic chemotherapies or biologic agents (e.g.
             azacitidine, decitabine, histone deacetylase inhibitors, tyrosine kinase inhibitors,
             hematopoietic growth factors, interferon, but excluding hydroxyurea and
             cyclophosphamide) for at least 2 weeks prior to starting induction chemotherapy

          -  Patients must be off radiation therapy or chemotherapy 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) of starting induction chemotherapy

          -  All adverse events (excluding alopecia, acne, rash) due to agents administered more
             than 2 weeks earlier should recover to =&lt; grade 1; patients with hematologic
             malignancies are expected to have hematologic abnormalities at study entry; these
             abnormalities which are thought to be primarily related to the underlying leukemia,
             are not considered to be toxicities (adverse events [AE]) and do not need to resolve
             to =&lt; grade 1

          -  Patients with therapy-related AML or MDS should have not received prior cumulative
             anthracycline (daunorubicin equivalent) lifetime dose &gt; 450 mg/m^2

          -  Cytoreduction allowed:

               -  Hydroxyurea, corticosteroids, leukapheresis can be used prior to start of
                  induction chemotherapy

               -  Cyclophosphamide up to dose 50-60 mg/kg is allowed for cytoreduction, but must be
                  given at least 7+/- 2 days before start of induction chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 50%)

          -  Total bilirubin &lt; 2.0 mg/dL unless due to Gilbert's disease, hemolysis or leukemia

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 5 Ã— institutional upper limit of normal unless due to leukemic infiltration

          -  Creatinine =&lt; 2.0 mg/dL

          -  Left ventricular ejection fraction &gt;= 45%

          -  Female who is able to become pregnant must have a negative pregnancy test with a
             sensitivity of at least 25 mIU/mL within 10-14 days prior to and again within 24 hours
             of starting pomalidomide; female who is able to become pregnant must either commit to
             continued abstinence from heterosexual intercourse or begin two acceptable methods of
             birth control, one highly effective and one additional effective method at the same
             time; female who is able to become pregnant must agree to ongoing pregnancy testing;
             men must agree to use a latex condom during sexual contact with female who is able to
             become pregnant even if they had vasectomy for the duration of study participation,
             and 28 days after completion of pomalidomide administration; all patients must be
             counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal
             exposure while taking pomalidomide; should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately

          -  Ability to understand and the willingness to sign a written informed consent document;
             consent will be obtained by day 14 of AcDVP-16 induction regimen

          -  Known human immunodeficiency virus (HIV) infected patients (HIV testing will not be
             performed as a part of screening) on combination antiretroviral therapy are eligible
             for inclusion; the use of zidovudine is not allowed

        Exclusion Criteria:

          -  Patients who are receiving any other investigational agents or who have received
             pomalidomide in the past

          -  Patients with known active central nervous system leukemia should be excluded from
             this clinical trial; patient receiving intrathecal chemotherapy prophylaxis should not
             receive pomalidomide for &gt;= 3 days after administration

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to pomalidomide (e.g. lenalidomide, thalidomide) or other agents used in
             study

          -  The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide, lenalidomide or similar drugs in the past

          -  Uncontrolled intercurrent illness including, but not limited to, active and
             uncontrolled infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, mental deficits, psychiatric illness or history or
             social situations that would limit compliance with study requirements; patients with
             infection under active treatment and controlled with antibiotics are eligible

          -  Any other medical condition that in opinion of investigator would place patient at
             increased risk for toxicity during pomalidomide treatment (i.e. history of recurrent
             or serious thromboembolic events)

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with pomalidomide

          -  Known positive patients for infectious hepatitis, type A, B, C

          -  Active graft-versus-host disease (GVHD) following allogeneic stem cell transplant for
             non-AML condition (ex. MDS, MPN, lymphoid malignancy, aplastic anemia) requiring
             ongoing use of immunosuppressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivana Gojo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University/Sidney Kimmel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2014</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

